Lilly's diabetes drug trumps Sanofi's in late-stage trials

Sept 4 (Reuters) - Eli Lilly and Co said its diabetes drug was more effective than Sanofi SA's approved drug, Lantus, in reducing blood sugar levels in late-stage trials.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.